- Home
- ABUS vs ATLC Comparison
ABUS vs ATLC Comparison
Compare ABUS & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- ATLC
- Stock Information
- Founded
- ABUS 2005
- ATLC 1996
- Country
- ABUS United States
- ATLC United States
- Employees
- ABUS N/A
- ATLC N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- ATLC Finance: Consumer Services
- Sector
- ABUS Health Care
- ATLC Finance
- Exchange
- ABUS Nasdaq
- ATLC Nasdaq
- Market Cap
- ABUS 670.3M
- ATLC 732.1M
- IPO Year
- ABUS N/A
- ATLC 1999
- Fundamental
- Price
- ABUS $3.43
- ATLC $50.96
- Analyst Decision
- ABUS Strong Buy
- ATLC Strong Buy
- Analyst Count
- ABUS 4
- ATLC 5
- Target Price
- ABUS $5.50
- ATLC $62.00
- AVG Volume (30 Days)
- ABUS 610.0K
- ATLC 49.3K
- Earning Date
- ABUS 07-31-2025
- ATLC 08-07-2025
- Dividend Yield
- ABUS N/A
- ATLC N/A
- EPS Growth
- ABUS N/A
- ATLC 21.75
- EPS
- ABUS N/A
- ATLC 5.17
- Revenue
- ABUS $6,403,000.00
- ATLC $424,877,000.00
- Revenue This Year
- ABUS $3.35
- ATLC $273.30
- Revenue Next Year
- ABUS N/A
- ATLC $11.92
- P/E Ratio
- ABUS N/A
- ATLC $9.97
- Revenue Growth
- ABUS N/A
- ATLC 17.71
- 52 Week Low
- ABUS $2.71
- ATLC $25.44
- 52 Week High
- ABUS $4.73
- ATLC $64.70
- Technical
- Relative Strength Index (RSI)
- ABUS 50.84
- ATLC 48.74
- Support Level
- ABUS $3.46
- ATLC $49.11
- Resistance Level
- ABUS $3.65
- ATLC $54.45
- Average True Range (ATR)
- ABUS 0.12
- ATLC 1.65
- MACD
- ABUS -0.00
- ATLC 0.08
- Stochastic Oscillator
- ABUS 35.29
- ATLC 49.35
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About ATLC Atlanticus Holdings Corporation
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.